ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission and rheumatoid arthritis"

  • Abstract Number: 1933 • 2018 ACR/ARHP Annual Meeting

    Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation

    Stefano Alivernini1, Barbara Tolusso1, Aziza Elmesmari2, Laura Bui3, Giusy Peluso1, Maria Rita Gigante1, Samuel Finlay2,4, Luca Petricca1, Clara Di Mario1, Simone Perniola1,5, Anna Laura Fedele1, Francesco Federico3, Iain B. McInnes2,4, Gianfranco Ferraccioli1, Mariola Kurowska-Stolarska2,6 and Elisa Gremese1, 1Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, 2Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University of the Sacred Heart, Rome, Italy, 4Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Glasgow, United Kingdom, 5Department of Verona - University of Verona (ITALY), Verona, Italy, 6Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Rome, Italy

    Background/Purpose: Flares of immune-mediated inflammatory diseases, as Rheumatoid Arthritis (RA) occur unpredictably representing a major burden for patients and clinicians. We aimed to dissect the…
  • Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting

    Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study

    Carmen Bejerano1, Natividad Oreiro1, Carlos Fernandez-Lopez2, Jose A Pinto-Tasende1, Antonio Atanes1, Bruno De Aspe1, Genaro Graña Gil1, Mercedes Freire1, Manuel Acasuso3, Sonia Pertega4, Francisco J. de Toro1 and Francisco J Blanco1, 1Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, 2Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, 3Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, 4Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

    Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
  • Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting

    Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis

    Yoshiya Tanaka1, Hisashi Yamanaka2, Naoki Ishiguro3, Nobuyuki Miyasaka4, Katsuyoshi Kawana5, Katsutoshi Hiramatsu6, Aki Kuroki5 and Tsutomu Takeuchi7, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Abbvie, Tokyo, Japan, 6Medical, Abbvie, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
  • Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting

    Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity

    Francesca Ometto1, Costantino Botsios2, Livio Bernardi1, Bernd Raffeiner2,3, Leonardo Punzi4 and Andrea Doria4, 1Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, 2Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 3Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, 4Department of Medicine - DIMED, University of Padova, Padova, Italy

    Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
  • Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting

    Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study

    Takao Fujii1, Masahiro Sekiguchi2, Kiyoshi Matsui2, Masayasu Kitano2, Motomu Hashimoto3, Koichiro Ohmura4, Aihiro Yamamoto5, Hideko Nakahara6, Keiji Maeda7, Akira Yokota8, Kenji Miki9, Naoki Shimmyo10, Takanori Kuroiwa11, Kosaku Murakami12, Yoshio Ozaki13, Kenshi Higami14, Ichiro Yoshii15, Yuji Nozaki16, Takashi Ikawa17, Satoshi Morita18, Yutaka Kawahito5, Norihiro Nishimoto19, Tsuneyo Mimori4 and Hajime Sano2, 1Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, 3The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 6Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 7Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 8Yokota Clinic for Rheumatology, Osaka, Japan, 9Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, 10Kashiba Asahigaoka Hospital, Kashiba, Japan, 11Department of Rheumatology, Yukioka Hospital, Osaka, Japan, 12Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Kansai Medical University Hirakata Hospital, Hirakata, Japan, 14Department of Rheumatology, Higami Hospital, Nara, Japan, 15Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, 16Kinki University Faculty of Medicine, Sayama, Japan, 17Osaka Rehabilitation Hospital, Hannan, Japan, 18Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, 19Osaka Rheumatology Clinic, Osaka, Japan

    Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
  • Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting

    Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12

    Bernd Raffeiner1, Costantino Botsios2, Francesca Ometto2, Mariagrazia Canova2, Livio Bernardi2, Cristiana Vezzari2, Silvano Todesco2, Paolo Sfriso2 and Leonardo Punzi2, 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 2Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy

    Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
  • Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting

    Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

    Josef S. Smolen1, D. Aletaha2, D. Gruben3, J. D. Bradley4, S. H. Zwillich3, S. Krishnaswami3, B. Benda5 and C. Mebus6, 1Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Pfizer Inc., Groton, CT, 4Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, 5Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
  • Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting

    Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results

    Yoshiya Tanaka1, Shintaro Hirata1, Shunsuke Fukuyo1, Masao Nawata2, Satoshi Kubo2, Kunihiro Yamaoka2 and Kazuyoshi Saito1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
  • Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting

    Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study

    Yukitomo Urata1, Yoshihide Nakamura2 and Ken-ichi Furukawa3, 1Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 2Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 3Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

    Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology